Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
WASHINGTON (AP) — The Supreme Court on Monday declined, for now, to hear a challenge to a Maryland l2024-05-21Chinese orchestra group performs at Kenya's oldest university
Members of the traditional instrument orchestra of China's Nanjing University perform with a Ken2024-05-21AI takes center stage at Beijing Film Fest
The poster for the 14th Beijing International Film Festival is revealed on March 28, 2024. [Photo co2024-05-21Charlotte Dawson puts on a VERY leggy display in a thigh
Charlotte Dawson put on a very leggy display in a leopard print dress whilst on holiday in the Maldi2024-05-21Messi in and Dybala out in Argentina squad for pre
BUENOS AIRES, Argentina (AP) — Lionel Messi is in and Paulo Dybala is out of Argentina’s squad for f2024-05-21Central African Republic FM to visit China
At the invitation of Member of the Political Bureau of the Communist Party of China Central Committe2024-05-21
atest comment